

# Synthesis of 6- and 7-Membered *N*-Heterocycles Using $\alpha$ -Phenylvinylsulfonium Salts


Johnathan V. Matlock,<sup>†</sup> Thomas D. Svejstrup,<sup>†</sup> Pradip Songara,<sup>†</sup> Sarah Overington,<sup>†</sup> Eoghan M. McGarrigue,<sup>\*,‡</sup> and Varinder K. Aggarwal<sup>\*,†</sup>

<sup>†</sup>School of Chemistry, University of Bristol, Cantock's Close, BS8 1TS, Bristol, U.K.

<sup>‡</sup>Centre for Synthesis and Chemical Biology, UCD School of Chemistry, University College Dublin, Belfield, Dublin 4, Ireland

**S** Supporting Information

**ABSTRACT:** A concise synthesis of stereodefined C-substituted morpholines, piperazines, azepines, and oxazepines in moderate to excellent yields (27% to 75%) is reported by reaction of 1,2- or 1,3-amino alcohol/1,2- or 1,3-diamine with an  $\alpha$ -phenylvinylsulfonium salt. High levels of regio- and diastereoselectivity (from 2:1 to >20:1) are observed through judicious choice of base ( $\text{Cs}_2\text{CO}_3$ ) and solvent ( $\text{CH}_2\text{Cl}_2$ ). Reactions are performed at ambient temperature and open to air and do not require anhydrous solvent. The deprotection of the *N*-sulfonamide protecting groups (*N*-Ts and *N*-Ns) is also demonstrated. Factors affecting regio- and diastereocontrol are discussed.




The question “are we making the right molecules?” has hung over the pharmaceutical industry for many years.<sup>1</sup> Njardarson analyzed all U.S. FDA approved small molecule drugs<sup>2</sup> and found that 21% (71)<sup>3</sup> contained saturated 6-membered *N*-heterocycles with an additional heteroatom. Clearly, morpholines and piperazines are in “the right molecules” category, and this demand continues to stimulate new methods for their synthesis. Current state of the art methods for the synthesis of saturated *N*-heterocycles containing an additional heteroatom include Ti-mediated hydroamination/reduction,<sup>4</sup> Pd-mediated carboamination,<sup>5</sup> photoredox C–H arylation,<sup>6</sup> nucleophilic substitution,<sup>7</sup> Lewis acid catalyzed ring expansion of 3-oxetanone spirocycles,<sup>8</sup> ammonium persulfate mediated  $\text{S}_{\text{N}}2$ -type ring opening of aziridines with halogenated alcohols,<sup>9</sup> and the SnAP reagents developed by Bode.<sup>10</sup> The latter method is the most attractive in terms of generality, substitution patterns, and lack of protecting groups that it can accommodate. However, the use of toxic tin reagents unfortunately detracts from the chemistry and its applicability in an industrial setting. In this paper, we report a new complementary method for the synthesis of di- and trisubstituted saturated *N*-heterocycles bearing a second heteroatom with very high regio- and diastereocontrol using our recently developed  $\alpha$ -arylvinylsulfonium salt.<sup>11</sup>


We have previously investigated the synthesis of saturated *N*-heterocycles bearing an additional heteroatom using vinylsulfonium salt **2** (Scheme 1).<sup>7,12</sup> This methodology has proven to be versatile for the construction of *N*-heterocycles bearing an ethylene bridge.<sup>13</sup> In order to access more substituted *N*-heterocycles, we considered the use of vinylsulfonium salts with either  $\alpha$ - or  $\beta$ -substituents (**5** and **6**) (Scheme 1). However, for a successful process, the challenges of controlling both regioselectivity during the initial conjugate addition (attack

## Scheme 1. Synthesis of Saturated *N,X*-Heterocycles Using Vinylsulfonium Salts

Previous Work:



This Work:



through O vs N) and diastereoselectivity would need to be overcome. In this paper, we describe our success in achieving these goals.

Received: September 1, 2015

Published: September 30, 2015

Initially, we investigated the annulation of 1,2-amino alcohols **9a–c** with the known  $\beta$ -phenylvinylsulfonium salt **10**.<sup>14</sup> Treatment of **9a–c** with DBU as a base gave morpholines **11a–c** in good yields and with complete regioselectivity (conjugate addition through O rather than N) (Table 1, entries

Table 1. Synthesis of Substituted Morpholines with **10**


entry	substrate	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	<b>11</b> <sup>a</sup> (%)	<b>12</b> <sup>a</sup> (%)	dr <sup>b</sup>
1	<b>9a</b>	Me	Me	H	67	13	
2	<b>9b</b>	( <i>R</i> )-Me	H	( <i>S</i> )-Ph	53	21	1.1:1
3	<b>9c</b>	( <i>S</i> )-Bn	H	H	59	8	1.5:1

<sup>a</sup>Isolated yields. <sup>b</sup>Diastereoselectivity was determined from <sup>1</sup>H NMR of the crude reaction mixtures.

1–3). Although the initial results were promising, these reactions suffered from several problems, highlighting some of the challenges faced. Incomplete conversion was observed for all substrates, and a competing side reaction involving elimination of the intermediate sulfonium salt was also observed, leading to the isolation of side products **12a–c**. Furthermore, both morpholines **11b** and **11c** were formed as ~1:1 mixtures of diastereomers.

We then investigated  $\alpha$ -phenylvinylsulfonium salt **13**.<sup>11</sup> Initial reaction screening focused on the (*R*)-alanine-derived *N*-tosyl-protected amino alcohol **14a**. Treatment of **14a** with **13**, in the presence of DBU as the base (Table 2, entry 1), led

Table 2. Optimization of Reaction Conditions with **13**



entry	base (equiv)	<b>13</b> (equiv)	time (h)	<b>15/16</b> <sup>a</sup> (%)	isomeric ratio <sup>b</sup> <b>15a:16a</b>
1	DBU (3.5)	1.2	24	9	2:1
2	DBU (3.5)	2 × 1	24 <sup>c</sup>	45	2:1
3	Cs <sub>2</sub> CO <sub>3</sub> (3.5)	1.2	24	18	20:1
4	Cs <sub>2</sub> CO <sub>3</sub> (3.5)	3	24	64	20:1
5	Cs <sub>2</sub> CO <sub>3</sub> (2 × 2)	3	6	71	20:1
6	Cs <sub>2</sub> CO <sub>3</sub> (2 × 2)	2 × 1	6	76 (73) <sup>d,e</sup>	20:1

<sup>a</sup><sup>1</sup>H NMR yields of **15a** + **16a** calculated from the crude reaction mixture using 1,3,5-trimethoxybenzene as the internal standard. <sup>b</sup>Isomeric ratio represents the ratio of the two major isomers formed during the reaction (**15a** and **16a**). <sup>c</sup>0 °C then rt. <sup>d</sup>Isolated yield in parentheses. <sup>e</sup>Identical reaction performed on gram scale open to air using bench CH<sub>2</sub>Cl<sub>2</sub> as the solvent gave 77% (72%) of **15a**.


to the formation of the desired compound **15a**, albeit in poor yield as a mixture of isomers. An improvement in yield was achieved through batchwise addition of **13** (Table 2, entry 2). Preparative HPLC separation and analysis of the two major isomers by <sup>13</sup>C/HSQC NMR indicated that a 2:1 mixture of regioisomers had been formed. The relative stereochemistry of the major regioisomer was confirmed by X-ray crystallography (*cis*-**15a**), and the relative stereochemistry of the minor regioisomer was determined to be *cis*-**16a** through analysis of <sup>3</sup>J<sub>HH</sub> coupling constants. These initial results also confirmed that excellent levels of diastereoselectivity were observed. Further optimization of the reaction conditions eventually revealed Cs<sub>2</sub>CO<sub>3</sub>/CH<sub>2</sub>Cl<sub>2</sub> as the base and solvent of choice for this reaction. Pleasingly, this base and solvent system led to complete regioselectivity, with conjugate addition occurring through O, generating almost exclusively *cis*-**15a** (Table 2, entries 3–6). Batchwise addition of both Cs<sub>2</sub>CO<sub>3</sub> and **13** was necessary to ensure that the reaction went to completion, due to competing decomposition of **13** under the reaction conditions over time. The operational simplicity of the reaction should also be noted, allowing the chemistry to be performed over short reaction times, open to air and on a gram scale (Table 2, entry 6).

With an optimized procedure in hand, the substrate scope of the reaction was then investigated (Scheme 2). Amino alcohols derived from enantiopure amino acids valine **14b**, phenylalanine **14c**, tryptophan **14d**, and serine **14e** all underwent the desired transformation to give morpholines **15b–e** in excellent yields and with excellent regio-/diastereoselectivity. Furthermore, **15b–d** could be isolated as single isomers by recrystallization, albeit in slightly reduced yields. In contrast to products **15a–e**, the *tert*-butyl ester morpholine **15f** was formed as a 2:1 mixture of regioisomers, which we were unable to separate. More hindered substrates **14g** and **14h** also participated in the reaction to give the desired morpholines **15g** and **15h** in good yields, with excellent regioselectivities. Unfortunately, under these optimized conditions substrates bearing the protecting groups Boc, Cbz, Troc, Bn, COCF<sub>3</sub>, or unprotected nitrogen failed, giving either unreacted starting material or polar compounds which could not be identified. However, the related nosyl-protected<sup>15</sup> amino alcohol **14i** was compatible, giving morpholine **15i** in slightly lower yield and with lower regioselectivity in comparison to the tosyl protected amino alcohol **14a**.

The methodology is also applicable to substrates **14j–l** with substituents  $\alpha$  to oxygen and/or nitrogen leading to the formation of di- and trisubstituted morpholines **15j–l** in good yields and with moderate selectivities. For substrate **15l**, excellent regioselectivity was achieved, but lower diastereoselectivity was observed. The synthesis of *C*-substituted piperazines was also possible starting from 1,2-diamine substrates **14m–o**. The corresponding piperazines **15m–o** were formed in good yields and with good diastereo- (**15m**) and regioselectivities (**15n**) for some substrates but low diastereoselectivities for others (**15o**). Finally, the application of  $\alpha$ -phenylvinylsulfonium salt **13** to the synthesis of substituted azepines and oxazepines was also conducted, and the 7-membered heterocycles **15p** and **15q** were formed in moderate yields but with very high regioselectivity.


A rationale for the observed regio- and diastereoselectivities is proposed (Scheme 3). The observed regioselectivity results from a faster rate of reaction of the more nucleophilic oxygen nucleophile, despite its lower concentration [*Ts*NH (p*K*<sub>a</sub> 17,

Scheme 2. Substrate Scope




<sup>a</sup>Isolated yield after column chromatography. <sup>b</sup>Ratio of regioisomers determined from the  $^1\text{H}$  NMR of the crude reaction mixtures prior to purification. <sup>c</sup>Isolated yield after recrystallization to obtain a single regioisomer. <sup>d</sup>*trans-15f* was formed as a 1:1 mixture of diastereomers (see the Supporting Information). The yield reported is the isolated yield after recrystallization which led to an enrichment of the *trans-15f* diastereomer. <sup>e</sup>*cis-15j* was formed as a 6:1:1:1 mixture of regioisomers and diastereomers. <sup>f</sup>*cis-15l* was formed as a 3:1 mixture of diastereomers. <sup>g</sup>NOE and  $^3J_{\text{HH}}$  analysis was used to confirm the relative stereochemistry of *cis-15n*. <sup>h</sup>*cis-15o* was formed as a 2:1 mixture of diastereomers as determined by analysis of  $^3J_{\text{HH}}$  coupling constants (see the Supporting Information).

Scheme 3. Rationale for the Observed Regio- and Diastereoselectivity



DMSO<sup>16</sup>) vs OH ( $\text{p}K_{\text{a}}$  30, DMSO<sup>17</sup>]. The diastereoselectivity of this transformation is set during the  $\text{S}_{\text{N}}2$  displacement, which proceeds through two diastereomeric transition states A and B. The major diastereomer results from placing all substituents in pseudo-equatorial positions (A), while the minor diastereomer results from placing the phenyl group in a pseudoaxial position (B). The cyclized product C then ring flips because of unfavorable gauche interactions to give the major isomer *cis-15a*. Although *cis-15a* has an unfavorable 1,3-diaxial interaction, this conformation is observed in solution [ $^3J_{\text{HH}}$  PhCH (d,  $J$  4.0 Hz)]. Conformer C would be expected to have one large  $^3J_{\text{HH}}$  (ax-ax) and one small coupling  $^3J_{\text{HH}}$  (ax-eq) which are not observed. We have observed similar effects in thiomorpholines previously.<sup>18</sup>

To demonstrate synthetic utility, *N*-Ts morpholine *cis-15a* was deprotected using a sodium/naphthalene reduction and isolated as the hydrochloride salt **17** in excellent yield as a single diastereoisomer (Scheme 4). The  $\text{S}_{\text{N}}\text{Ar}$  deprotection of

Scheme 4. Deprotection of Morpholines<sup>a</sup>

<sup>a</sup>Conditions: (A) Na/naphthalene (3 equiv), DME (0.1 M),  $-78^\circ\text{C}$ , 30 min; (B) 2-mercaptoethanol (2 equiv), DBU (2 equiv), acetone (0.2 M), rt, 30 min; (C) HCl (1 M in Et<sub>2</sub>O, 1.5 equiv), rt, 5 min.

*N*-Ns morpholine *cis-15i* with 2-mercaptoethanol and DBU<sup>19</sup> was also achieved, leading to the HCl salt **17** in excellent yield. As signals overlapped in the  $^1\text{H}$  NMR of **17**, it was Boc protected to give **18**, which allowed the coupling constants to be measured; these showed a good correlation with the parent *N*-sulfonamides *cis-15a* and *cis-15i*.

In conclusion, we have developed a highly practical route to stereodefined C-substituted morpholines, piperazines, azepines, and oxazepines in moderate to excellent yields using our recently developed  $\alpha$ -phenylvinylsulfonium salt **13**. The method exhibits high levels of regio- and diastereoselectivity

and is operationally simple. Reactions are conducted open to air, with nonanhydrous solvents, on a gram scale using readily available starting materials and reagents. The methodology enables rapid construction of spatially defined substituents and heteroatoms in small molecules from flexible acyclic precursors, features which will resonate with drug discovery programs.

## ■ ASSOCIATED CONTENT

### Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.orglett.5b02516.

<sup>1</sup>H NMR signals (XLSX)

Experimental procedures and spectroscopic data for all novel compounds (PDF)

## ■ AUTHOR INFORMATION

### Corresponding Authors

\*Tel: + (353)17162418. E-mail: eoghan.mcgarrigle@ucd.ie.

\*Tel: + 44 (0)1179546315. Fax: + (44) (0)117-925-1295. E-mail: v.aggarwal@bristol.ac.uk.

### Notes

The authors declare no competing financial interest.

## ■ ACKNOWLEDGMENTS

J.V.M. and P.S. thank the EPSRC and the Bristol Chemical Synthesis Centre for Doctoral Training for studentship support (EP/G036764/1). E.M.M. thanks Science Foundation Ireland and Marie-Curie-COFUND for a SIRG award (Grant No. 11/SIRG/B2154). We thank Dr. C. Butts and Dr. H. Sparkes (University of Bristol) for NMR spectra and X-ray assistance, respectively.

## ■ REFERENCES

- (1) Lovering, F. *MedChemComm* **2013**, *4*, 515.
- (2) Vitaku, E.; Smith, D. T.; Njardarson, J. T. *J. Med. Chem.* **2014**, *57*, 10257.
- (3) Of 1,595 small molecule drugs analyzed, 640 contain N-heterocyclic rings. Within this data set, 21% (71 compounds) contain morpholine or piperazine rings.
- (4) Zhai, H.; Borzenko, A.; Lau, Y. Y.; Ahn, S. H.; Schafer, L. L. *Angew. Chem., Int. Ed.* **2012**, *51*, 12219.
- (5) Leathen, M. L.; Rosen, B. R.; Wolfe, J. P. *J. Org. Chem.* **2009**, *74*, 5107.
- (6) McNally, A.; Prier, C. K.; MacMillan, D. W. C. *Science* **2011**, *334*, 1114.
- (7) (a) Yar, M.; McGarrigle, E. M.; Aggarwal, V. K. *Angew. Chem., Int. Ed.* **2008**, *47*, 3784. (b) Yar, M.; McGarrigle, E. M.; Aggarwal, V. K. *Org. Lett.* **2009**, *11*, 257.
- (8) Burkhard, J. A.; Wagner, B.; Fischer, H.; Schuler, F.; Müller, K.; Carreira, E. M. *Angew. Chem., Int. Ed.* **2010**, *49*, 3524.
- (9) Sun, H.; Huang, B.; Lin, R.; Yang, C.; Xia, W. *Beilstein J. Org. Chem.* **2015**, *11*, 524.
- (10) (a) Vo, C.-V. T.; Mikutis, G.; Bode, J. W. *Angew. Chem., Int. Ed.* **2013**, *52*, 1705. (b) Luescher, M. U.; Vo, C.-V. T.; Bode, J. W. *Org. Lett.* **2014**, *16*, 1236. (c) Vo, C.-V. T.; Luescher, M. U.; Bode, J. W. *Nat. Chem.* **2014**, *6*, 310. (d) Siau, W.-Y.; Bode, J. W. *J. Am. Chem. Soc.* **2014**, *136*, 17726. (e) Geoghegan, K.; Bode, J. W. *Org. Lett.* **2015**, *17*, 1934. (f) Luescher, M. U.; Bode, J. W. *Angew. Chem., Int. Ed.* **2015**, *54*, 10884. (g) Luescher, M. U.; Geoghegan, K.; Nichols, P. L.; Bode, J. W. *Aldrichimica Acta* **2015**, *48*, 43.
- (11) Matlock, J. V.; Fritz, S. P.; Harrison, S. A.; Coe, D. M.; McGarrigle, E. M.; Aggarwal, V. K. *J. Org. Chem.* **2014**, *79*, 10226.

(12) (a) Fritz, S. P.; Mumtaz, A.; Yar, M.; McGarrigle, E. M.; Aggarwal, V. K. *Eur. J. Org. Chem.* **2011**, *2011*, 3156. (b) Yar, M.; Fritz, S. P.; Gates, P. J.; McGarrigle, E. M.; Aggarwal, V. K. *Eur. J. Org. Chem.* **2012**, *2012*, 160.

(13) (a) Mukaiyama, T.; Yamanaka, H.; Yamane, Y. *Heterocycles* **2004**, *63*, 2813. (b) Xie, C.; Han, D.; Liu, J.; Xie, T. *Synlett* **2009**, *2009*, 3155. (c) Xie, C.; Han, D.; Hu, Y.; Liu, J.; Xie, T. *Tetrahedron Lett.* **2010**, *51*, 5238. (d) An, J.; Chang, N.-J.; Song, L.-D.; Jin, Y.-Q.; Ma, Y.; Chen, J.-R.; Xiao, W.-J. *Chem. Commun.* **2011**, *47*, 1869. (e) Bornholdt, J.; Felding, J.; Kristensen, J. L. *J. Org. Chem.* **2010**, *75*, 7454. (f) Fukunaga, Y.; Uchida, T.; Ito, Y.; Matsumoto, K.; Katsuki, T. *Org. Lett.* **2012**, *14*, 4658. (g) Kwon, S. H.; Lee, S. M.; Byun, S. M.; Chin, J.; Kim, B. M. *Org. Lett.* **2012**, *14*, 3664. (h) Hicks, F.; Hou, Y.; Langston, M.; McCarron, A.; O'Brien, E.; Ito, T.; Ma, C.; Matthews, C.; O'Bryan, C.; Provencal, D.; Zhao, Y.; Huang, J.; Yang, Q.; Heyang, L.; Johnson, M.; Sitang, Y.; Yuqiang, L. *Org. Process Res. Dev.* **2013**, *17*, 829. (i) Huang, R.; Xie, C.; Huang, L.; Liu, J. *Lett. Org. Chem.* **2013**, *10*, 195.

(14) Matsuo, J.-I.; Yamanaka, H.; Kawana, A.; Mukaiyama, T. *Chem. Lett.* **2003**, *32*, 392.

(15) Kan, T.; Fukuyama, T. *Chem. Commun.* **2004**, 353.

(16) Bordwell, F. G.; Fried, H. E.; Hughes, D. L.; Lynch, T. Y.; Satish, A. V.; Whang, Y. E. *J. Org. Chem.* **1990**, *55*, 3330.

(17) Olmstead, W. N.; Margolin, Z.; Bordwell, F. G. *J. Org. Chem.* **1980**, *45*, 3295.

(18) Hansch, M.; Illa, O.; McGarrigle, E. M.; Aggarwal, V. K. *Chem. - Asian J.* **2008**, *3*, 1657.

(19) Greene, T. W.; Wuts, P. G. M. *Protective Groups in Organic Synthesis*, 3rd ed.; Wiley: Hoboken, 1999.